Richmond Pharmacology is excited to join the JSCPT Annual Meeting 2026 in Tokyo, Japan, on 27-28 November 2026.

Bringing together experts in clinical pharmacology and therapeutics, this meeting serves as a key platform for advancing drug development, optimizing clinical trial methodologies, and fostering global collaboration in clinical research.

Representing Richmond Pharmacology

  • Dr Jörg Taubel, Chief Executive Officer
  • Dr Ulrike Lorch, Chief Medical Director
  • Stephen Wilkinson, Business Development Manager
  • Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
  • Minoru Takada, Japanese Business Development Executive

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Advances in clinical pharmacology and therapeutic innovation
  • Optimizing trial design for complex drug development programs
  • Regulatory pathways for novel therapies
  • Patient-centric approaches and recruitment strategies
  • Collaboration between academia, industry, and regulators

Connect With Us

If you are attending JSCPT Annual Meeting 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event